Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Assistive Technology P...
The Assistive Technology Program provides information about, and funding for, devices that help...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
Study: MS drug may slow brain shrinkage
August 31, 2018
Results from a clinical trial of more than 250 participants with progressive multiple sclerosis revealed that ibudilast was better than a placebo in slowing down brain shrinkage. The study showed the main side effects of ibudilast were gastrointestinal and headaches. The researchers said the trial’s results point towards a potential new therapy to help people with progressive MS.
A team of researchers across 28 clinical sites in a brain imaging study investigated whether ibudilast was better than a placebo in reducing the progression of brain atrophy, or shrinkage, in patients with progressive MS. The study was supported by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health. In the study, 255 patients were randomized to take up to 10 capsules of ibudilast or placebo per day for 96 weeks. Every six months, the participants underwent MRI brain scans.
The study showed that ibudilast slowed down the rate of brain atrophy compared to placebo. Researchers discovered that although both groups experienced atrophy, the brains of the patients in the placebo group shrank on average 2.5 milliliters more over two years compared to the ibudilast group. The whole adult human brain has a volume of approximately 1,350 milliliters. However, it is unknown whether that difference had an effect on symptoms or loss of function.
There was no significant difference between the groups in the number of patients who reported adverse effects. The most common side effects associated with ibudilast were gastrointestinal, including nausea and diarrhea, as well as headaches and depression.
Future research will test whether reducing brain shrinkage affects thinking, walking, and other problems in people with MS. In addition, future studies will examine whether ibudilast slows the progression of disability in MS patients.
The study was published in the
New England Journal of Medicine
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more